Convergence Investment Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Convergence Investment Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$883.2 - $1071.19 $168,691 - $204,597	191 New	191 $200,000
Q3 2023 Nov 02, 2023	BUY	$692.45 - $844.37 $206,350 - $251,622	298 New	298 $245,000
Q2 2022 Aug 05, 2022	SELL	$548.35 - $738.84 $49,899 - $67,234	-91 Reduced 12.67%	627 $371,000
Q1 2022 Apr 26, 2022	BUY	$595.12 - $698.43 $58,321 - $68,446	98 Added 15.81%	718 $501,000
Q4 2021 Jan 25, 2022	BUY	$543.48 - $670.97 $336,957 - $416,001	620 New	620 $392,000
Q2 2018 Aug 07, 2018	SELL	$284.6 - $344.99 $33,867 - $41,053	-119 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$315.82 - $393.78 $37,582 - $46,859	119 New	119 $41,000

1,497

82.8M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $72.4B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Convergence Investment Partners, LLC with notifications on news.